Cefiderocol Antimicrobial Susceptibility Testing Considerations: the Achilles' Heel of the Trojan Horse?
antimicrobial susceptibility testing
broth microdilution
cefiderocol
disk diffusion
Journal
Journal of clinical microbiology
ISSN: 1098-660X
Titre abrégé: J Clin Microbiol
Pays: United States
ID NLM: 7505564
Informations de publication
Date de publication:
17 12 2020
17 12 2020
Historique:
pubmed:
31
7
2020
medline:
24
6
2021
entrez:
31
7
2020
Statut:
epublish
Résumé
Cefiderocol (formerly S-649266) is a novel siderophore-conjugated cephalosporin with activity against a broad array of multidrug-resistant (MDR), aerobic Gram-negative bacilli. The siderophore component binds iron and uses active iron transport for drug entry into the bacterial periplasmic space. The cephalosporin moiety is the active antimicrobial component, structurally resembling a hybrid between ceftazidime and cefepime. Like other β-lactam agents, the principal bactericidal activity of cefiderocol occurs via inhibition of bacterial cell wall synthesis by binding of penicillin-binding proteins (PBPs) and inhibiting peptidoglycan synthesis, leading to cell death. Iron concentrations need to be taken into consideration when
Identifiants
pubmed: 32727829
pii: JCM.00951-20
doi: 10.1128/JCM.00951-20
pmc: PMC7771437
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Cephalosporins
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2020 American Society for Microbiology.
Références
Burnham JP, Olsen MA, Kollef MH. Re-estimating annual deaths due to multidrug-resistant organism infections. Infect Control Hosp Epidemiol. 2019;40:112–113.
doi: 10.1017/ice.2018.304
O'Neil J. Tackling drug-resistant infections globally: final report and recommendations. 2016.
Antibiotic resistance threats in the United States. 2019.
Doi Y. Treatment options for carbapenem-resistant gram-negative bacterial infections. Clin Infect Dis. 2019;69:S565–S575.
doi: 10.1093/cid/ciz830
Choi JJ, McCarthy MW. Cefiderocol: a novel siderophore cephalosporin. Expert Opin Invest Drugs. 2018;27:193–197.
doi: 10.1080/13543784.2018.1426745
Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, Idowu T, Domalaon R, Schweizer F, Zhanel MA, Lagace-Wiens PRS, Walkty AJ, Noreddin A, Lynch Iii JP, Karlowsky JA. Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant Gram-negative bacilli. Drugs. 2019;79:271–289.
doi: 10.1007/s40265-019-1055-2
Fetcroja. 2020.
Simner PJ, McAdam AJ. What's special about cefiderocol? A micro-comic strip. J Clin Microbiol. 2020;58:e00256-20.
doi: 10.1128/JCM.00256-20
Page MGP. The role of iron and siderophores in infection, and the development of siderophore antibiotics. Clin Infect Dis. 2019;69:S529–S537.
doi: 10.1093/cid/ciz825
Huband MD, Ito A, Tsuji M, Sader HS, Fedler KA, Flamm RK. Cefiderocol MIC quality control ranges in iron-depleted cation-adjusted Mueller-Hinton broth using a CLSI M23-A4 multi-laboratory study design. Diagn Microbiol Infect Dis. 2017;88:198–200.
doi: 10.1016/j.diagmicrobio.2017.03.011
Ito A, Sato T, Ota M, Takemura M, Nishikawa T, Toba S, Kohira N, Miyagawa S, Ishibashi N, Matsumoto S, Nakamura R, Tsuji M, Yamano Y. In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria. Antimicrob Agents Chemother. 2017;62:e01454-17.
doi: 10.1128/AAC.01454-17
Ito A, Kohira N, Bouchillon SK, West J, Rittenhouse S, Sader HS, Rhomberg PR, Jones RN, Yoshizawa H, Nakamura R, Tsuji M, Yamano Y. In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria. J Antimicrob Chemother. 2016;71:670–677.
doi: 10.1093/jac/dkv402
Sato T, Yamawaki K. Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin. Clin Infect Dis. 2019;69:S538–S543.
doi: 10.1093/cid/ciz826
Karlowsky JA, Hackel MA, Tsuji M, Yamano Y, Echols R, Sahm DF. In vitro activity of defiderocol, a siderophore cephalosporin, against gram-negative bacilli isolated by clinical laboratories in North America and Europe in 2015–2016: SIDERO-WT-2015. Int J Antimicrob Agents. 2019;53:456–466.
doi: 10.1016/j.ijantimicag.2018.11.007
Kazmierczak KM, Tsuji M, Wise MG, Hackel M, Yamano Y, Echols R, Sahm DF. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-beta-lactamase-producing isolates (SIDERO-WT-2014 study). Int J Antimicrob Agents. 2019;53:177–184.
doi: 10.1016/j.ijantimicag.2018.10.007
Kohira N, West J, Ito A, Ito-Horiyama T, Nakamura R, Sato T, Rittenhouse S, Tsuji M, Yamano Y. In vitro antimicrobial activity of a siderophore cephalosporin, s-649266, against Enterobacteriaceae clinical isolates, including carbapenem-resistant strains. Antimicrob Agents Chemother. 2016;60:729–734.
doi: 10.1128/AAC.01695-15
Yamano Y. In vitro activity of cefiderocol against a broad range of clinically important Gram-negative bacteria. Clin Infect Dis. 2019;69:S544–S551.
doi: 10.1093/cid/ciz827
Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF. In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of Gram-negative bacilli collected worldwide in 2014 to 2016. Antimicrob Agents Chemother. 2017;62:e01968-17.
doi: 10.1128/AAC.01968-17
Cefiderocol FDA briefing document. 2019.
Delgado-Valverde M, Conejo MDC, Serrano L, Fernandez-Cuenca F, Pascual A. Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia. J Antimicrob Chemother. 2020;75:1840–1849.
doi: 10.1093/jac/dkaa117
Golden AR, Adam HJ, Baxter M, Walkty A, Lagace-Wiens P, Karlowsky JA, Zhanel GG. In vitro activity of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacilli isolated from patients in Canadian intensive care units. Diagn Microbiol Infect Dis. 2020;97:115012.
doi: 10.1016/j.diagmicrobio.2020.115012
Iregui A, Khan Z, Landman D, Quale J. Activity of cefiderocol against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii endemic to medical centers in New York City. Microb Drug Resist. 2020;97:722–726.
doi: 10.1089/mdr.2019.0298
Morris CP, Bergman Y, Tekle T, Fissel J, Tamma PD, Simner PJ. Cefiderocol antimicrobial susceptibility testing against multidrug-resistant Gram-negative bacilli: a comparison of disk diffusion to broth microdilution. J Clin Microbiol. 2021;59:e01649-20.
doi: 10.1128/JCM.01649-20
Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF. In vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant Gram-negative bacilli from North America and Europe, including carbapenem-nonsusceptible isolates (SIDERO-WT-2014 Study). Antimicrob Agents Chemother. 2017;61:e00093-17.
doi: 10.1128/AAC.00093-17
Ito A, Nishikawa Ishii R, Kuroiwa M, Kurihara N, Sakikawa I, Ota T, Rokushima M, Tsuiji M, Sato T, Yamano Y. Mechanisms of cefiderocol high MIC mutants obtained in non-clinical studies. 2018.
Kawai A, McElheny CL, Iovleva A, Kline EG, Sluis-Cremer N, Shields RK, Doi Y. Structural basis of reduced susceptibility to ceftazidime-avibactam and cefiderocol in Enterobacter cloacae due to AmpC R2 loop deletion. Antimicrob Agents Chemother. 2020;64:e00198-20.
doi: 10.1128/AAC.00198-20
Albano M, Karau MJ, Schuetz AN, Patel R. Comparison of agar dilution to broth microdilution for testing in vitro activity of cefiderocol against Gram-negative bacilli. J Clin Microbiol. 2020;59:e00966-20.
doi: 10.1128/JCM.00966-20
Ito A, Nishikawa T, Matsumoto S, Yoshizawa H, Sato T, Nakamura R, Tsuji M, Yamano Y. Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2016;60:7396–7401.
doi: 10.1128/AAC.01405-16
June, 2017 AST agenda summary minutes. 2017.
Performance standards for antimicrobial susceptibility testing; thirtieth informational supplement. 2020.
Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF. Reproducibility of broth microdilution MICs for the novel siderophore cephalosporin, cefiderocol, determined using iron-depleted cation-adjusted Mueller-Hinton broth. Diagn Microbiol Infect Dis. 2019;94:321–325.
doi: 10.1016/j.diagmicrobio.2019.03.003
Sasaki K, Ikuta K, Tanaka H, Ohtake T, Torimoto Y, Fujiya M, Kohgo Y. Improved quantification for non-transferrin-bound iron measurement using high-performance liquid chromatography by reducing iron contamination. Mol Med Rep. 2011;4:913–918.
doi: 10.3892/mmr.2011.518
Swenson JM, Killgore GE, Tenover FC. Antimicrobial susceptibility testing of Acinetobacter spp. by NCCLS broth microdilution and disk diffusion methods. J Clin Microbiol. 2004;42:5102–5108.
doi: 10.1128/JCM.42.11.5102-5108.2004
Critchley IA, Basker MJ. Conventional laboratory agar media provide an iron‐limited environment for bacterial growth. FEMS Microbiology Lett. 1988;50:35–39.
doi: 10.1111/j.1574-6968.1988.tb02907.x
June, 2019 AST agenda summary minutes. 2019.
CDC & FDA Antibiotic Resistance (AR) Isolate Bank. 2020.
Breakpoints for cefiderocol from EUCAST. 2020.
Cefiderocol injection. 2019.
Final summary minutes of the Antimicrobial Drugs Advisory Committee Meeting. 2019.